Bengaluru, July 21 -- One of India's key pharmaceutical API manufacturers was in focus today following the release of its Q1 FY26 results. The company posted a solid year-on-year growth in revenues and profitability, although sequentially, earnings remained under pressure.

With new capacity expansions and a strong backward integration strategy underway, the company is positioning itself to capitalize on emerging global opportunities, particularly in regulated markets.

The company in focus is Aarti Drugs Limited, which currently holds a market capitalization of Rs. 4,845 crore. The stock opened today at Rs. 525, higher than its previous close of Rs. 523.20, and touched an intraday high of Rs. 542, reflecting a gain of approximately 3.58 ...